Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Equity

Inhibikase Therapeutics (IKT) FCF Margin (2020 - 2023)

Historic FCF Margin for Inhibikase Therapeutics (IKT) over the last 4 years, with Q4 2023 value amounting to 344243100.0%.

  • Inhibikase Therapeutics' FCF Margin fell 3442375052300.0% to 344243100.0% in Q4 2023 from the same period last year, while for Sep 2024 it was 1724492300.0%, marking a year-over-year decrease of 17244866841700.0%. This contributed to the annual value of 6947.87% for FY2023, which is 73054900.0% up from last year.
  • Inhibikase Therapeutics' FCF Margin amounted to 344243100.0% in Q4 2023, which was down 3442375052300.0% from 5159.16% recorded in Q3 2023.
  • Inhibikase Therapeutics' FCF Margin's 5-year high stood at 200.41% during Q3 2020, with a 5-year trough of 344243100.0% in Q4 2023.
  • Its 4-year average for FCF Margin is 21539540.75%, with a median of 4540.49% in 2023.
  • As far as peak fluctuations go, Inhibikase Therapeutics' FCF Margin skyrocketed by 2000000000bps in 2022, and later plummeted by 2000000000bps in 2023.
  • Inhibikase Therapeutics' FCF Margin (Quarter) stood at 555.42% in 2020, then plummeted by -37833bps to 210690.17% in 2021, then soared by 97bps to 5594.77% in 2022, then plummeted by -6152840bps to 344243100.0% in 2023.
  • Its FCF Margin was 344243100.0% in Q4 2023, compared to 5159.16% in Q3 2023 and 3921.82% in Q2 2023.